8 min read · May 2026
Compounded GLP-1 Prices in Summer 2026: Complete Guide
Market snapshot: Compounded semaglutide pricing has dropped to $147-$350/month in mid-2026, driven by provider competition and regulatory pressure. This may be the lowest pricing window before potential 503B compounding restrictions take effect.
The compounded GLP-1 market in summer 2026 is in a strange position: prices are the lowest they've ever been, while the regulatory future is the most uncertain it's ever been. Here's the current pricing landscape across verified providers.
Compounded Semaglutide Pricing
| Provider | Starting Price | Maintenance Dose | Notes |
|---|---|---|---|
| Wellorithm | $147/mo | Ask provider | Lowest published starting price |
| Yucca Health | $146/mo (6-mo plan) | $146/mo flat | 6-month commitment required |
| Gala GLP-1 | $179/mo | $179/mo flat | No dose-tier increases |
| Care Bare Rx | $199/mo | Varies | Multi-vertical (WL + ED + NAD+) |
| Embody | $149 first month | $299/mo | Injectable semaglutide only |
| SHED | $297-$299/mo | $399/mo at 7.5mg+ | Dose-dependent pricing increase |
| SkinnyRx | $149/mo | Varies | Injectable, sublingual, tablets |
⚠️ Important: "Starting price" means the lowest dose during titration. Your maintenance dose (typically 2.4mg semaglutide) will cost more with some providers. Always ask what you'll pay at target dose.
Compounded Tirzepatide Pricing
| Provider | Starting Price | Notes |
|---|---|---|
| Yucca Health | $258/mo (6-mo plan) | Commitment discount |
| SkinnyRx | From $249/mo | Multiple formats available |
| SHED | From $297/mo | Higher doses cost more |
Brand-Name Pricing Comparison
| Medication | Cash Price | With Savings Card | Medicare BALANCE (July 2026) |
|---|---|---|---|
| Wegovy (semaglutide injectable) | ~$1,349/mo | Varies | $50/mo |
| Wegovy Pill (oral sema 25mg) | ~$299/mo | Varies | $50/mo |
| Zepbound (tirzepatide) | ~$1,060/mo | As low as $0 | $50/mo |
Why Prices May Not Stay This Low
The FDA's April 30, 2026 proposal to exclude GLP-1s from the 503B Bulks List signals that large-scale compounding may end within 12-18 months. If 503B facilities lose access, supply shrinks and 503A pharmacies face capacity constraints — both of which would push prices up.
Current pricing reflects maximum provider competition during the final window of regulatory tolerance. If you've been considering compounded GLP-1 treatment, the pricing fundamentals favor acting sooner rather than later.
Gala GLP-1
No dose-tier increases. Transparent pricing at every dose level.
Compounded medications are not FDA-approved.
Learn More Paid linkYucca Health
Deepest discount with commitment. Both semaglutide and tirzepatide available.
Compounded medications are not FDA-approved.
Learn More Paid linkEmbody
Lead anchor provider. Injectable semaglutide with physician oversight.
Compounded medications are not FDA-approved.
Learn More Paid linkCompare GLP-1 Providers Side by Side
See pricing, medications, and ratings for verified telehealth providers.
View Provider Comparison →Sources
- Provider websites: pricing verified May 2026.
- Novo Nordisk. Wegovy pricing, 2026.
- Eli Lilly. Zepbound pricing and savings program, 2026.
- FDA. 503B Bulks List Proposal, April 30, 2026.
Medical Disclaimer: This content is for informational purposes only and is not medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
FDA Notice: Compounded medications referenced in this article are not FDA-approved. Only brand-name GLP-1 medications (Wegovy, Zepbound, Ozempic, Mounjaro) carry FDA approval for their indicated uses.